Clinical manifestations and neuron-specific enolase cerebrospinal fluid concentration in HIV/AIDS patients with cerebral toxoplasmosis
https://doi.org/10.30629/2658-7947-2023-28-2-25-30
Abstract
Background. Cerebral toxoplasmosis (CT) is one of the most common cause of focal neurological defi cit in HIV/ AIDS group of patients. Timely diagnosis of CT and antiparasitic therapy contribute to decrease of lethal outcomes and disability.
Aim. To study neurological manifestations, cognitive functions and neuron-specifi c enolase (NSE) concentration in cerebrospinal fluid (CSF), in HIV/AIDS patients with CT.
Material and methods. The 35 patients (10 females and 25 males) from 28 to 50 years old with confirmed diagnosis of HIV/AIDS-associated CT were included in the investigation group. Neurological status, cognitive function and laboratory CSF changings had been studied in prospective investigation before and during the treatment with control points in the 1st and 10th days of the observation.
Results. The method of neurological manifestation of CT evaluation had been developed and implemented in practice. The association between neurological defi cit severity (movement and sensory disorders), cognitive decline and increasing CSF concentration of NSE in HIV/AIDS-associated CT was determined that demonstrates the activity of encephalitic process.
Conclusion. Dynamic evaluation of NSE concentration in CSF with clinical assessment of neurological manifestation in patients with HIV/AIDS-associated CT may be used for confirmation of specific antiparasitic treatment effectiveness and for increasing clinical criteria significance.
About the Authors
N. E. Seksyaev
Perm State Medical University named after Academician E.A. Wagner
Russian Federation
Russian Federation
Perm
Yu. V. Karakulova
Perm State Medical University named after Academician E.A. Wagner
Russian Federation
Russian Federation
Perm
D. Yu. Sosnin
Perm State Medical University named after Academician E.A. Wagner
Russian Federation
Russian Federation
Perm
References
1. Porter SB, Sande MA. Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. N Engl J Med. 1992;327(23):1643–1648. https://doi.org/10.1056/NEJM199212033272306
2. Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58(RR–4):1–CE4.
3. Safarpour H, Cevik M, Zarean M, Barac A, Hatam-Nahavandi K, Rahimi MT et al. Global status of Toxoplasma gondii infection and associated risk factors in people living with HIV. AIDS. 2020;34(3):469–474. https://doi.org/10.1097/QAD.0000000000002424
4. Vidal JE. HIV-Related Cerebral Toxoplasmosis Revisited: Current Concepts and Controversies of an Old Disease. J Int Assoc Provid AIDS Care. 2019;18:2325958219867315. https://doi.org/10.1177/2325958219867315
5. Bilgrami M, O’Keefe P. Neurologic diseases in HIV-infected patients. Handb Clin Neurol. 2014;121:1321–1344. https://doi.org/10.1016/B978-0-7020-4088-7.00090-0
6. Luft BJ, Remington JS. Toxoplasmic encephalitis in AIDS. Clin Infect Dis. 1992;15(2):211–222. https://doi.org/10.1093/clinids/15.2.211
7. Tsuge I, Matsuoka H, Nakagawa A, Kamachi Y, Aso K, Negoro T et al. Necrotizing toxoplasmic encephalitis in a child with the Xlinked hyper-IgM syndrome. Eur J Pediatr. 1998;157:735–737. https://doi.org/10.1007/s004310050925
8. Händel U, Brunn A, Drögemüller K, Müller W Deckert M., Schlüter D. Neuronal gp130 expression is crucial to prevent neuronal loss, hyperinflammation, and lethal course of murine Toxoplasma encephalitis. Am J Pathol. 2012;181(1):163–173. https://doi.org/10.1016/j.ajpath.2012.03.029
9. HIV infection and AIDS. Ed. by V.V. Pokrovskiy. Moscow: GEOTAR-Media; 2007:145 p. (In Russ.).
10. Ermak TN, Peregudova AB. Location of foci in cerebral toxoplasmosis in HIV-infected patient. Therapeutic archive. 2014;86(11):24–
11. (In Russ.). https://www.mediasphera.ru/issues/terapevticheskij-arkhiv/2014/11/030040-36602014115?ysclid=lcs6rsrkkc319578324 (дата обращения: 11.01.2023)
12. Cingolani A, De Luca A, Ammassari A, Murri R, Linzalone A, Grillo R et al. PCR detection of Toxoplasma gondii DNA in CSF for the differential diagnosis of AIDS-related focal brain lesions. J Med Microbiol. 1996;45(6):472–476. https://doi.org/10.1099/00222615-45-6-472
13. Alfonso Y, Fraga J, Fonseca C, Jiménez N, Pinillos T, DortaContreras AJ et al. Molecular diagnosis of Toxoplasma gondii infection in cerebrospinal fluid from AIDS patients. Cerebrospinal Fluid Res. 2009;6:2. Published 2009 Mar 6. https://doi.org/10.1186/1743-8454-6-2
14. Goncharov DB. The role of Toxoplasma gondii persistence in human clinical pathology. Microbiology, epidemiology and immunobiology. 2006;4:92–97. (In Russ.).
15. Hill D, Dubey JP. Toxoplasma gondii: transmission, diagnosis and prevention. Clin Microbiol Infect. 2002;8(10):634–640. https://doi.org/10.1046/j.1469-0691.2002.00485.x
16. Grant IH, Gold JW, Rosenblum M, Niedzwiecki D, Armstrong D. Toxoplasma gondii serology in HIV-infected patients: the development of central nervous system toxoplasmosis in AIDS. AIDS. 1990;4(6):519–521.
17. Isgrò MA, Bottoni P, Scatena R. Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects. Adv Exp Med Biol. 2015;867:125–143. https://doi.org/10.1007/978-94-017-7215-0_9
18. Oh SH, Lee JG, Na SJ, Park JH, Choi YC, Kim WJ. Prediction of early clinical severity and extent of neuronal damage in anterior-circulation infarction using the initial serum neuron-specific enolase level. Arch Neurol. 2003;60(1):37–41. https://doi.org/10.1001/archneur.60.1.37
19. Schmidt FM, Mergl R, Stach B, Jahn I, Gertz HJ, Schönknecht P. Elevated levels of cerebrospinal fluid neuron-specific enolase (NSE) in Alzheimer’s disease. Neurosci Lett. 2014;570:81–85. https://doi.org/10.1016/j.neulet.2014.04.007
20. Theofilidis A, Karakasi MV, Sofologi M, Konstantinidis G, Pavlidis P, Tegos Т, Nimatoudis J. Frontal Assessment Battery in the evaluation of patients with neurocognitive disorder due to the human immunodeficiency virus. Rev Colomb Psiquiatr (Engl Ed). 2021;50(2):66–69. https://doi.org/10.1016/j.rcpeng.2020.01.004
21. Torniainen-Holm M, Suvisaari J, Lindgren M, Härkänen T, Dickerson F, Yolken RH. The lack of association between herpes simplex virus 1 or Toxoplasma gondii infection and cognitive decline in the general population: An 11-year follow-up study. Brain Behav Immun. 2019;76:159–164. https://doi.org/10.1016/j.bbi.2018.11.016
Review
For citations:
Seksyaev N.E., Karakulova Yu.V., Sosnin D.Yu. Clinical manifestations and neuron-specific enolase cerebrospinal fluid concentration in HIV/AIDS patients with cerebral toxoplasmosis. Russian neurological journal. 2023;28(2):25-30. (In Russ.) https://doi.org/10.30629/2658-7947-2023-28-2-25-30
Views:
433
Email this article 